In recent years endoscopically controlled laser-induced thermal therapy (LITT) has been increasingly accepted as a minimally invasive method for palliation of advanced or recurrent head and neck or gastrointestinal cancer. Previous studies have shown that adjuvant chemotherapy can potentiate endoscopic laser thermal ablation ofobstructing tumors leading to improved palliation in advanced cancer patients. Eight patients with recurrent head and neck tumors volunteered to enroll as part of an ongoing phase II LITT clinical trial, and also elected to be treated with systemic chemotherapy (cisplatin, 80 mg/m2) followed 24 h later by palliative laser thermal ablation. Laser treatments were repeated in patients with residual disease or recurrence for a total of 27 LITT sessions. Four of the 8 patients treated with laser thermal chemotherapy remained alive after a median follow-up of 12 months. Ofthe 12 tumor sites treated, complete responses were located in the oral cavity (3), oropharynx (1), hypopharynx (1), maxillary sinus (1), and median survival for these patients was 9.5 months.
INTRODUCTION
Laser induced thermal therapy (LITT) using the Nd:YAG laser via endoscopic fiberoptics has been increasingly accepted as an effective palliative method for tumor ablation [1] [2] [3] [4] . LITT facilitated by endoscopy is of great value for less invasive palliation of advanced obstructing cancers of the head and neck, as well as for the gastrointestinal and bronchial tracts by endoscopic recanalization [1, 2, 4] . High photo-thermal laser energy levels are delivered to the area of maximum obstruction but lower levels to the tumor margins, which frequently remain undertreated resulting in recurrences [1] [2] [3] [4] .
Despite well documented tumor responses and an apparently increased patient survival after LITT, the need for repeated palliative laser sessions suggests that more effective treatment may be possible by combined drug and laser therapy [5] [6] [7] [8] [9] [10] [11] . Cisplatin in combination with other anticancer agents has been successfully used together with Nd YAG laser therapy for endoscopic palliative treatment of advanced esophageal and gastric cancer [6] [7] [8] [9] [10] [11] and is a current clinical protocol as an alternative to radiation therapy for treatment of retinoblastomas as reported by several investigators [12] [13] [14] . The rationale for combined laser and chemotherapy is based on the observation that tumor recurrence after LITT occurs at the margin and that drug enhancement by hyperthermia at these sites could eliminate or reduce this tumor regrowth [7, 8] .
PATIENTS AND METHODS
Based on reports that chemotherapy enhances palliative endoscopic laser therapy in advanced esophageal and gastric cases [6] [7] [8] [9] [10] [11] , the authors began a pilot study from The beam was maintained for 5-7 s on each target spot to achieve an energy density of 1600 to 2200 J/cm 2 per application. After carbonization of the tumor, debris was removed by suction. Following completion of debulking, the tumor bed with margins of 10 mm was treated again with the laser in the same fashion using a similar energy density. This produced a deeper layer ofphotoablation and better tumor eradication as well as photocoagulation of smaller vessels.
All patients with recurrent neck tumors needed ultrasound assistance (UTZ) to facilitate localization ofthe tumor in relation to the carotid artery and ensure that laser energy deposition remained away from vital structures, as described previously [15] .
After treatment all patients were followed by repeat visits to the outpatient clinic every Detailed results of these treatments are included in Table II. A 52-year-old male (patient #2) was unresponsive to conventional treatment. He presented with presented with a T4NOM0 squamous cell carcinoma of the floor of mouth had an apparent curative response after a single session ofcombined laser and cisplatin therapy with no evidence of tumor recurrence during 4 years follow-up (Fig. 2) . Biopsies performed at 2.5 years after initial treatment were negative and this patient remains active with a good quality of life.
Minor side-effects of the initial treatment phase with cisplatin and laser were common to most of the patients including a sensation of weakness with no objective findings in 4 patients and nausea with vomiting in 2 patients. These symptoms spontaneously resolved within a few days except in patient # 8 who responded with mild alopecia (grade 2 NIH toxicity score). No intra-operative adverse medical reactions were seen when Nd: YAG laser LITT was administered after systemic cisplatin administration. This combined treatment was well tolerated in 7 patients at the selected laser power and drug levels, causing no discernible adverse effects to overlaying soft tissue or adjacent structures. As a palliative form of therapy, most laser treatments were performed on an outpatient basis (74%) and median survival in this series of patients was 9.5 months. The survival curve for the entire study is shown in Fig. 3 .
DISCUSSION
Local recurrence after endoscopic laser thermal palliation is frequently related to residual disease from [8] .
Cisplatin combined with other chemotherapy agents in different regimens has been the drug of choice in several laser endoscopic palliative studies [9] [10] [11] . Mason [11] [11] .
Accumulating evidence indicates that heat induction causes ultrastructural changes in tumor cell membranes leading to increased membrane transport of drugs and altered cellular metabolism [16, 17] . Higher CDDP uptake after heating also enhances cytotoxicity in proliferating cancer cells and stimulates protein kinases to induce tumor apoptosis [18] . Studies of CDDP binding to DNA have shown that hyperthermia induces more DNA adducts, contributes to increased tumor growth delay, and amplifies interstrand crosslinks by cisplatinum [19] [20] [21] [22] [23] . Together, these results provide strong evidence that synergistic effects of heat and cisplatinum are likely to improve therapeutic response of recurrent head and neck tumors following combined drug and laser treatment.
A drug implant of cisplatinum with collagen as a protein matrix and epinephrine, (CDDP/gel, or IntradoseTM) allows higher intratumor drug levels to be maintained for nearly 24 h [24] . This slow release drug gel has been found to be safe and feasible for palliation of esophageal as well as head and neck and liver tumors [24] . The [5, 25, 26] . Currently, patients with advanced head and neck cancer are palliated at UCLA either by laser ablation in a phase II study or by intralesional cisplatin injection (CDDP/ epi-gel, phase III study) with clear evidence of tumor regression in a number of patients, but with eventual recurrence in the majority of cases [15, 24] .
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An obvious next step is to combine intratumor cisplatin injections with interstitial Nd: YAG laser therapy for cancer treatment [5, 26] .
The options for active palliation of local symptoms in inoperable patients are usually very limited [2, 15] . Although the current study was based on a small number of patients with heterogeneous tumor size and locations, the benefits of combined therapy appeared to be substantial in three cases. Four ofthe 8 patients remain alive, 3 in tumor remission with a current median follow-up of 12 months. This favorable outcome is possibly related to adequate cisplatin perfusion of the margin tumor regions 24 h after systemic administration of chemotherapy combined with LITT [8, 11, 14] 
